We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin (CARSKIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02883556
Recruitment Status : Completed
First Posted : August 30, 2016
Last Update Posted : January 13, 2021
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Tracking Information
First Submitted Date  ICMJE August 25, 2016
First Posted Date  ICMJE August 30, 2016
Last Update Posted Date January 13, 2021
Actual Study Start Date  ICMJE March 27, 2017
Actual Primary Completion Date March 23, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 29, 2016)
Response rate (RR) [ Time Frame: 15 weeks ]
Response rate (RR) at 15 weeks (RECIST v.1.1) in the whole sample by CT or MRI Response Evaluation Criteria in Solid Tumors with central radiology review
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 17, 2020)
  • Safety profile (NCI CTCAE v4.0) [ Time Frame: up to 28 months ]
    Advers event and serious adverse event status
  • RR in PD-L1-positive patients [ Time Frame: 15 weeks ]
    To assess in the whole sample and in PD-L1 positive patients
  • Disease Control Rate using RECIST and modified RECIST v.1.1 [ Time Frame: 15 weeks ]
    Controled by the radiological evaluation
  • RR using modified RECIST 1.1 [ Time Frame: 15 weeks ]
    Controled by the radiological evaluation
  • RR using RECIST and modified RECIST v.1.1 [ Time Frame: 24 weeks ]
    Controled by the radiological evaluation
  • Best RR using RECIST and modified RECIST v.1.1 [ Time Frame: 24 months ]
    The best response was collected after all radiological evaluation completion
  • Overall Survival (OS) [ Time Frame: up to 24 months ]
    Survival status
  • Progression Free Survival by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
    Controled by the radiological evaluation
  • Duration of response (DOR) by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
    Controled by the radiological evaluation
  • Duration of control by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
    Controled by the radiological evaluation
  • Time to disease progression by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
    Controled by the radiological evaluation
Original Secondary Outcome Measures  ICMJE
 (submitted: August 29, 2016)
  • Safety profile (NCI CTCAE v4.0) [ Time Frame: up to 28 months ]
  • RR in PD-L1-positive patients To assess in the whole sample and in PD-L1 positive patients [ Time Frame: 15 weeks ]
  • Disease Control Rate using RECIST and modified RECIST v.1.1 [ Time Frame: 15 weeks ]
  • RR using modified RECIST 1.1 [ Time Frame: 15 weeks ]
  • RR using RECIST and modified RECIST v.1.1 [ Time Frame: 24 weeks ]
  • Best RR using RECIST and modified RECIST v.1.1 [ Time Frame: 24 months ]
  • Overall Survival (OS) [ Time Frame: up to 24 months ]
  • Progression Free Survival by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
  • Duration of response (DOR) by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
  • Duration of control by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
  • Time to disease progression by RECIST 1.1 and modified RECIST 1.1 [ Time Frame: up to 24 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Official Title  ICMJE Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Brief Summary The purpose of this study is to assess the efficacy and safety of pembrolizumab in patient with locally advanced or metastatic squamous cell carcinoma of the skin
Detailed Description

Agents blocking the Programmed Cell Death 1(PD1)/Programmed Cell Death 1-Ligand 1 (PD-L1) pathway have demonstrated objective, durable tumor regressions in patients with advanced solid malignancies and efficacy has been linked to PD-L1 expression. PD-L1 expression by tumour cells is the strongest single predictor of response to anti-PD1 therapy (J Taube, R Anders et al, Clin Cancer Res 2014). Pembrolizumab (MK-3475) is a high-affinity humanized monoclonal anti-PD1 antibody. It leads to dual PD1-ligand blockade of PD-L1 and PD-L2 that may reactivate the immune surveillance and elicit anti-tumour response. It has antitumor activity in melanoma and NSCLC (phase III trials). Pembrolizumab might be of interest in unresectable squamous cell carcinomas of the skin (SCCS).

Approximately 20% to 30% of non-melanoma skin cancers are SCCS. Most patients with primary SCCS have an excellent prognosis, but SCCS can progress to advanced stages that are impossible to treat by surgical excision or radiotherapy. Few therapeutic options are available for these tumors. Conventional chemotherapy, such as cisplatin-based combinations, has some efficacy, but the toxic effects of these combinations often prohibit their use in elderly patients. Epidermal Growth Factor (EGFR) signaling antagonists have activity only in a subset of patients. New therapeutic options are needed for patients with advanced SCCS.

No trial evaluating pembrolizumab in human SCCS is ongoing. Investigators hypothesize that:

i) PD-L1 is expressed in SCCS as in HNSCC ii) pembrolizumab may be effective as a single agent in patients with unresectable SCCS iii) Efficacy of pembrolizumab is correlated to PD-L1 expression in SCCS.

Investigators therefore intend to determine the efficacy and safety of single agent pembrolizumab in all patients and in patients with PD-L1-positive unresectable SCCS naïve of chemotherapy and of EGFR inhibitors.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Squamous Cell
Intervention  ICMJE Drug: Pembrolizumab
200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
Other Name: MK-3475, KEYTRUDA
Study Arms  ICMJE Experimental: Pembrolizumab 200 mg
Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
Intervention: Drug: Pembrolizumab
Publications * Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob JJ, Dreno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudie H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guegan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Levy V; Groupe de Cancerologie Cutanee30. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. J Clin Oncol. 2020 Sep 10;38(26):3051-3061. doi: 10.1200/JCO.19.03357. Epub 2020 Jul 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 17, 2020)
57
Original Estimated Enrollment  ICMJE
 (submitted: August 29, 2016)
39
Actual Study Completion Date  ICMJE December 15, 2020
Actual Primary Completion Date March 23, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Be willing and able to provide written informed consent/assent for the trial
  • Be more than 18 years of age on day of signing informed consent.
  • Be either affiliated to, or a beneficiary of, a social security category
  • Have metastatic disease, or locally advanced disease not amenable to surgery with documented progression
  • Be willing and able to undergo pre-treatment baseline biopsy of the tumor
  • PD-L1+ or PD-L1- tumors
  • Have measurable disease based on RECIST 1.1
  • Have a performance status of 0 or 1 on the Easter Cooperative Oncology Group (ECOG) Performance Scale.
  • Demonstrate adequate organ function as defined in Table 3, all screening labs should be performed within 10 days of treatment initiation.
  • Have recovered from major surgery or radiation therapy
  • Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.
  • Female subjects of childbearing potential should be willing to use 1 method of birth control before the first dose of study therapy through 120 days after the last dose of study therapy. (Reference Section 7.5.1).

Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Exclusion Criteria:

  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks or 5 half-lives (minimum 14 days), whichever is shorter, prior to the first dose of treatment.
  • Has received prior therapy with either chemotherapy or targeted therapy for the present tumor
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
  • Has received radiation therapy within 4 weeks prior to study Day 1
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
  • Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., Hepatitis C Virus RNA [qualitative] is detected).
  • Has known history of, or any evidence of active, non-infectious pneumonitis.
  • Has an active infection requiring systemic therapy
  • Has received a live vaccine within 30 days of planned start of study therapy.
  • Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Fluenz tetra®) are live attenuated vaccines, and are not allowed.
  • Hypersensitivity to pembrolizumab or any of its excipients.
  • Has a known additional malignancy. Exceptions include i) basal cell carcinoma of the skin or other squamous cell carcinoma of the skin or in situ cervical cancer, ii) history of another non blood malignancy that has undergone potentially curative therapy without recurrence for more than 2 years.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with brain metastases may participate provided they are stable (without evidence of progression by imaging for at least eight weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02883556
Other Study ID Numbers  ICMJE P151202
2016-002076-28 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Assistance Publique - Hôpitaux de Paris
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Assistance Publique - Hôpitaux de Paris
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Eve MAUBEC, Pr Assistance Publique - Hôpitaux de Paris
Study Director: Zahia Ben-Abdesselam, CP Unité de Recherche clinique
PRS Account Assistance Publique - Hôpitaux de Paris
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP